Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basiliximab for Stable Noninfectious Uveitis
NCT00646425Phase 2Terminated
- Sponsor
- Cerimon Pharmaceuticals, Inc.
- Start
- May 2008
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in noninfectious uveitis (NIU) comparing Basiliximab with Placebo (2 arms). Primary endpoint: Increase in disease activity at 16 weeks. Started May 2008; status: terminated.
02
Drugs
basiliximab
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT00646425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00646425.